{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:47:36Z","timestamp":1782535656718,"version":"3.54.5"},"reference-count":33,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Immune checkpoint inhibitors (ICIs) are standard treatment for melanoma and non-small cell lung cancer (NSCLC), yet evidence on their effectiveness in older adults remains limited due to underrepresentation in clinical trials. This study assessed long-term, age-stratified outcomes of ICI treatment in real-world clinical practice. Methods: This nationwide observational study used data from the Netherlands Cancer Registry on patients with synchronous stage IV melanoma or NSCLC who received first-line ICIs between 2018 and 2023. Melanoma treatments included nivolumab plus ipilimumab or anti-PD-1 monotherapy; NSCLC treatments included pembrolizumab with or without chemotherapy. Primary outcomes were five-year overall survival (5-yr OS) and three-year conditional survival (3-yr CS), stratified by age. Results: A total of 11,140 patients were included, consisting of 583 patients with melanoma and 10,557 with NSCLC. In the melanoma population, 5-yr OS was 43.8%. Patients aged \u2265 75 years had a 5-yr OS of 30.8% and a 3-yr CS of 58.7%. In NSCLC treated with pembrolizumab monotherapy, 5-yr OS was 23.1%; among patients aged \u2265 75 years, 5-yr OS was 15.6% and 3-yr CS was 46.6%. Pembrolizumab combined with chemotherapy resulted in a 5-yr OS of 14.6%, with corresponding 5-yr OS of 8.4% and 3-yr CS of 35.5% in patients aged \u2265 75 years. Conclusions: This registry-based analysis suggests that ICI are associated with durable long-term survival in real-world patients with stage IV melanoma or NSCLC, including selected older adults. These findings are in line with outcomes of clinical trials, but further research is needed on predictors of ICI effectiveness in the older population.<\/jats:p>","DOI":"10.3390\/cancers18122019","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:13:37Z","timestamp":1782195217000},"page":"2019","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-958X","authenticated-orcid":false,"given":"Eline G. M.","family":"Steenhuis","sequence":"first","affiliation":[{"name":"Department of Pulmonology, Isala, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8345-8802","authenticated-orcid":false,"given":"Lieke M.","family":"van Disseldorp","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Rijnkade 5, 3511 LC Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5631-9629","authenticated-orcid":false,"given":"Femke J. C.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Rijnkade 5, 3511 LC Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"van Schayk","sequence":"additional","affiliation":[{"name":"Department of Information and Advice, Netherlands Comprehensive Cancer Organisation (IKNL), Rijnkade 5, 3511 LC Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn","family":"Suijkerbuijk","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Louwman","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Rijnkade 5, 3511 LC Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia N. S.","family":"d\u2019Hooghe","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Onze Lieve Vrouwen Gasthuis, Oosterpark 9, 1091 AC Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A. M.","family":"Damhuis","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Rijnkade 5, 3511 LC Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-0974","authenticated-orcid":false,"given":"Wouter H.","family":"van Geffen","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lieber, A., Makai, A., Orosz, Z., Kardos, T., Isaac, S.J., Tornyi, I., and Bittner, N. (2024). The role of immunotherapy in early-stage and metastatic NSCLC. Pathol. Oncol. Res., 4.","DOI":"10.3389\/pore.2024.1611713"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"Kudaba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101192","DOI":"10.1016\/j.esmoop.2023.101192","article-title":"Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: Results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)","volume":"8","author":"Gridelli","year":"2023","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jgo.2018.06.009","article-title":"Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper","volume":"10","author":"Bastiaannet","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.chest.2022.02.027","article-title":"Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis","volume":"162","author":"Komici","year":"2022","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","article-title":"Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy","volume":"9","author":"Voruganti","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: A meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00262-020-02779-2","article-title":"Efficacy of immune checkpoint inhibitors in elderly patients aged\u2009\u2265\u200975 years","volume":"70","author":"Petrelli","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103081","DOI":"10.1016\/j.eclinm.2025.103081","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"81","author":"Yao","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-14-2154","article-title":"Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time","volume":"21","author":"Hieke","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lambert, P.C., Dickman, P.W., and Rutherford, M.J. (2015). Comparison of different approaches to estimating age standardized net survival. BMC Med. Res. Methodol., 15.","DOI":"10.1186\/s12874-015-0057-3"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJGM.S435001","article-title":"Immunotherapy in Older Patients with Cancer: A Narrative Review","volume":"17","author":"Smith","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115145","DOI":"10.1016\/j.ejca.2024.115145","article-title":"Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience","volume":"214","author":"Bichon","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"de Glas, N.A., Bastiaannet, E., van den Bos, F., van der Veldt, A.A.M., Suijkerbuijk, K.P.M., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Boers-Sonderen, M.J., and van den Eertwegh, A.J. (2021). Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 13.","DOI":"10.3390\/cancers13112826"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2426641","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-Term Survival in Patients With Advanced Melanoma","volume":"7","author":"Jalving","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): A phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2022.40.16_suppl.9011","article-title":"Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (\u2265 70 years) patients with advanced non\u2013small cell lung cancer (Energy-GFPC 06-2015 study)","volume":"40","author":"Lena","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/cncr.34230","article-title":"Frailty and checkpoint inhibitor toxicity in older patients with melanoma","volume":"128","author":"Bruijnen","year":"2022","journal-title":"Cancer"},{"key":"ref_31","first-page":"CD013382","article-title":"Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status","volume":"7","author":"Gijtenbeek","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Udayakumar, S., Pandiarajan, S., Jessy Mercy, D., Suresh, J., Jagadeesh kumar, J.R., Girigoswami, A., and Girigoswami, K. (2025). Revolutionizing Cancer Vaccine: The Power of Advanced Nanotechnology. Chemistry, 7.","DOI":"10.3390\/chemistry7030097"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/2019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:29:46Z","timestamp":1782534586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18122019"],"URL":"https:\/\/doi.org\/10.3390\/cancers18122019","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}